Back to Search
Start Over
Soluble vascular endothelial growth factor receptor 2 and prognosis in patients with chronic heart failure
- Source :
- ESC Heart Failure, Vol 8, Iss 5, Pp 4187-4198 (2021)
- Publication Year :
- 2021
- Publisher :
- Wiley, 2021.
-
Abstract
- Abstract Aims Endothelial cell vascular endothelial growth factor receptor 2 (VEGFR‐2) plays a pivotal role in angiogenesis, which induces physiological cardiomyocyte hypertrophy via paracrine signalling between endothelial cells and cardiomyocytes. We investigated whether a decrease in circulating soluble VEGFR‐2 (sVEGFR‐2) levels is associated with poor prognosis in patients with chronic heart failure (HF). Methods and results We performed a multicentre prospective cohort study of 1024 consecutive patients with HF, who were admitted to hospitals due to acute decompensated HF and were stabilized after initial management. Serum levels of sVEGFR‐2 were measured at discharge. Patients were followed up over 2 years. The outcomes were cardiovascular death, all‐cause death, major adverse cardiovascular events (MACE) defined as a composite of cardiovascular death and HF hospitalization, and HF hospitalization. The mean age of the patients was 75.5 (standard deviation, 12.6) years, and 57% were male. Patients with lower sVEGFR‐2 levels were older and more likely to be female, and had greater proportions of atrial fibrillation and anaemia, and lower proportions of diabetes, dyslipidaemia, and HF with reduced ejection fraction (
Details
- Language :
- English
- ISSN :
- 20555822
- Volume :
- 8
- Issue :
- 5
- Database :
- Directory of Open Access Journals
- Journal :
- ESC Heart Failure
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.777770f2646d4641b8bb0377c526ee93
- Document Type :
- article
- Full Text :
- https://doi.org/10.1002/ehf2.13555